Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Replicate Study design for Brazil [Regulatives / Guidelines]

posted by Weidson – Brazil, 2018-05-22 22:51 (2528 d 20:34 ago) – Posting: # 18799
Views: 2,871

Dear balakotu

The ANVISA have adopted the EMA's Approach. However, for you use this approach you need to convince them that their drug is highly variable. I hope I have helped you.

Best Regards
Weidson C. de Souza

Edit: Post moved. [Helmut]

Complete thread:

Replicate Study design for Brazil balakotu 2018-05-21 13:31 [Regulatives / Guidelines]
- ABEL acc. to WHO Helmut 2018-05-21 16:47
- Replicate Study design for BrazilWeidson 2018-05-22 20:51

Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
21 visitors (0 registered, 21 guests [including 2 identified bots]).
Forum time: 19:25 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas. Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz